Zur Kurzanzeige

dc.creatorMessinis I.E., Messini C.I., Anifandis G., Daponte A.en
dc.date.accessioned2023-01-31T08:59:21Z
dc.date.available2023-01-31T08:59:21Z
dc.date.issued2021
dc.identifier10.1016/j.rbmo.2021.01.017
dc.identifier.issn14726483
dc.identifier.urihttp://hdl.handle.net/11615/76566
dc.description.abstractDuring ovarian stimulation for IVF–embryo transfer treatment, a premature LH surge may lead to progesterone elevation that disrupts endometrial maturation and affects the probability of pregnancy following fresh embryo transfer. Preventing this LH surge and progesterone elevation using gonadotrophin-releasing hormone (GnRH) analogues is considered a standard practice. The same policy applies to cycles in which the ‘freeze-all’ protocol has been selected from the outset (e.g. donors), but the need for this has not been discussed. Moreover, in ‘freeze-all’ cycles, exogenous progesterone administration tends to replace GnRH antagonists, without reducing efficacy after embryo transfer in frozen-thawed cycles. Nevertheless, as exogenous progesterone is expected to have the same impact on the endometrium as endogenous progesterone, it is clear that, unlike in fresh cycles, in ‘freeze-all’ cycles an endogenous LH surge prevention does not seem necessary. Therefore, both GnRH antagonists and exogenous progesterone appear to be redundant in ‘freeze-all’ cycles, and in this context the indications for the use of GnRH analogues in ovarian stimulation protocols need to be revisited. © 2021en
dc.language.isoenen
dc.sourceReproductive BioMedicine Onlineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85100679809&doi=10.1016%2fj.rbmo.2021.01.017&partnerID=40&md5=daafdae5c2ded4f30f6c2e698e67ab9b
dc.subjectdesogestrelen
dc.subjectdydrogesteroneen
dc.subjectgestagenen
dc.subjectgonadorelin agonisten
dc.subjectgonadorelin antagonisten
dc.subjectluteinizing hormoneen
dc.subjectmedroxyprogesterone acetateen
dc.subjectprogesteroneen
dc.subjectgonadorelinen
dc.subjectluteinizing hormoneen
dc.subjectprogesteroneen
dc.subjectclinical outcomeen
dc.subjectembryo transferen
dc.subjectendometriumen
dc.subjectfemaleen
dc.subjectfertility preservationen
dc.subjectfollicular phaseen
dc.subjecthumanen
dc.subjectluteinizationen
dc.subjectluteinizing hormone releaseen
dc.subjectmeta analysis (topic)en
dc.subjectnonhumanen
dc.subjectNoteen
dc.subjectoocyte cryopreservationen
dc.subjectoocyte donoren
dc.subjectoocyte maturationen
dc.subjectoocyte retrievalen
dc.subjectovary hyperstimulationen
dc.subjectpregnancyen
dc.subjectpregnancy outcomeen
dc.subjectblooden
dc.subjectovulation inductionen
dc.subjectproceduresen
dc.subjectFemaleen
dc.subjectGonadotropin-Releasing Hormoneen
dc.subjectHumansen
dc.subjectLuteinizing Hormoneen
dc.subjectOvulation Inductionen
dc.subjectProgesteroneen
dc.subjectElsevier Ltden
dc.titleExogenous progesterone for LH surge prevention is redundant in ovarian stimulation protocolsen
dc.typeotheren


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige